Meta-Analysis of First-Line Triple Therapy forHelicobacter pyloriEradication in Korea: Is It Time to Change?
Open Access
- 1 January 2014
- journal article
- research article
- Published by Korean Academy of Medical Sciences in Journal of Korean Medical Science
- Vol. 29 (5), 704-713
- https://doi.org/10.3346/jkms.2014.29.5.704
Abstract
Proton pump inhibitor (PPI)-based triple therapy consisting of PPI, amoxicillin, and clarithromycin, is the recommended first-line treatment for Helicobacter pylori infection. However, the eradication rate of triple therapy has declined over the past few decades. We analyzed the eradication rate and adverse events of triple therapy to evaluate current practices in Korea. A comprehensive literature search was performed up to August 2013 of 104 relevant studies comprising 42,124 patients. The overall eradication rate was 74.6% (95% confidence interval [CI], 72.1%-77.2%) by intention-to-treat analysis and 82.0% (95% CI, 80.8%-83.2%) by per-protocol analysis. The eradication rate decreased significantly from 1998 to 2013 (P < 0.001 for both intention-to-treat and per-protocol analyses). Adverse events were reported in 41 studies with 8,018 subjects with an overall incidence rate of 20.4% (95% CI, 19.6%-21.3%). The available data suggest that the effectiveness of standard triple therapy for H. pylori eradication has decreased to an unacceptable level. A novel therapeutic strategy is warranted to improve the effectiveness of first-line treatment for H. pylori infection in Korea.Keywords
This publication has 79 references indexed in Scilit:
- Prevalence and risk factors of Helicobacter pylori infection in Korea: Nationwide multicenter study over 13 yearsBMC Gastroenterology, 2013
- Effect of Helicobacter pylori Eradication According to the IL-8-251 Polymorphism in KoreansJournal of Korean Medical Science, 2012
- Comparison of sequential and 7-, 10-, 14-d triple therapy forHelicobacter pyloriinfectionWorld Journal of Gastroenterology, 2012
- Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in KoreaBritish Journal of Clinical Pharmacology, 2011
- The Influence of CYP2C19 Polymorphism on Eradication of Helicobacter pylori: A Prospective Randomized Study of Lansoprazole and RabeprazoleGut and Liver, 2010
- Helicobacter pylori treatment in the era of increasing antibiotic resistanceGut, 2010
- Helicobacter pyloriInfectionNew England Journal of Medicine, 2010
- New concepts of resistance in the treatment of Helicobacter pylori infectionsNature Clinical Practice Gastroenterology & Hepatology, 2008
- Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus ReportGut, 2007
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996